A Toxin-Based Delivery System That Shuttles Peptide Drugs Into the Cell Nucleus
A non-toxic form of Pseudomonas exotoxin A delivers peptide cargos directly to the nucleus, inhibiting the cancer-driving c-Myc protein at nanomolar concentrations.
Quick Facts
What This Study Found
PNDD1 delivers the c-Myc inhibitor peptide H1 to the nucleus and inhibits c-Myc-dependent transcription at nanomolar concentration, far exceeding the activity of H1 with conventional CPPs.
Key Numbers
Nanomolar potency (vs µM for CPP); killed DLBCL lines; spared normal B cells; delivered GST-sized cargo to nucleus
How They Did This
Fusion protein construction, nuclear localization tracking, c-Myc transcription inhibition assays, comparison with CPP-conjugated controls.
Why This Research Matters
Many cancer targets like c-Myc are in the nucleus, but most delivery systems only reach the cytoplasm. PNDD is the first system to efficiently deliver therapeutic peptides specifically to the nucleus.
The Bigger Picture
Nuclear-targeted peptide delivery could unlock an entire class of previously undruggable nuclear targets in cancer and other diseases.
What This Study Doesn't Tell Us
In vitro proof-of-concept. Immunogenicity of the bacterial exotoxin fragment needs assessment. In vivo delivery efficiency unknown.
Questions This Raises
- ?Would PNDD elicit immune responses in vivo due to its bacterial origin?
- ?Can this system deliver peptides to specific nuclear compartments?
- ?What is the therapeutic window between nuclear delivery and cytotoxicity?
Trust & Context
- Key Stat:
- Nanomolar c-Myc inhibition achieved by PNDD-delivered peptide, far exceeding conventional delivery approaches
- Evidence Grade:
- In vitro demonstration with strong functional data. Novel approach but early stage.
- Study Age:
- Published in 2020. Nuclear peptide delivery remains an active research challenge.
- Original Title:
- Targeting c-Myc with a novel Peptide Nuclear Delivery Device.
- Published In:
- Scientific reports, 10(1), 17762 (2020)
- Database ID:
- RPEP-05166
Evidence Hierarchy
Frequently Asked Questions
Why is getting drugs into the cell nucleus so hard?
Most drug delivery systems only get cargo into the cell's cytoplasm. The nucleus has its own membrane barrier with selective entry controls (nuclear pores). PNDD exploits a natural toxin pathway that goes directly from the cell surface to the nucleus.
What is c-Myc and why target it?
c-Myc is a transcription factor that drives many cancers by turning on genes for cell growth and division. Despite being one of the most important cancer targets, it has been considered 'undruggable' because it's inside the nucleus and lacks a traditional drug-binding pocket.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05166APA
Ting, Trinda Anne; Chaumet, Alexandre; Bard, Frederic Andre. (2020). Targeting c-Myc with a novel Peptide Nuclear Delivery Device.. Scientific reports, 10(1), 17762. https://doi.org/10.1038/s41598-020-73998-x
MLA
Ting, Trinda Anne, et al. "Targeting c-Myc with a novel Peptide Nuclear Delivery Device.." Scientific reports, 2020. https://doi.org/10.1038/s41598-020-73998-x
RethinkPeptides
RethinkPeptides Research Database. "Targeting c-Myc with a novel Peptide Nuclear Delivery Device..." RPEP-05166. Retrieved from https://rethinkpeptides.com/research/ting-2020-targeting-cmyc-with-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.